CNGB1 Antibody

What is CNGB1 and what is its molecular function?

CNGB1 (Cyclic nucleotide-gated cation channel beta-1) is a membrane protein that functions as a component of cyclic nucleotide-gated (CNG) ion channels. These channels are cation-selective and are opened by intracellular cyclic nucleotides such as cAMP and cGMP . The CNGB1 protein plays critical roles in sensory transduction, particularly in the retina and olfactory epithelium . It is widely expressed in various neurons and non-neuronal cells, where it contributes to signal transduction pathways .

The molecular structure of CNGB1 includes six transmembrane domains with a total length of 1251 amino acids in humans . The protein contains specific regions that interact with cyclic nucleotides and regulate channel opening. Research indicates CNGB1 primarily functions as a modulatory subunit in heteromeric CNG channels, affecting properties such as ligand sensitivity, ion permeation, and gating kinetics.

What applications are CNGB1 antibodies commonly used for?

CNGB1 antibodies are utilized in multiple research applications, with Western blot (WB) and ELISA being the most commonly validated techniques . The antibodies are also employed in immunohistochemistry (IHC) for examining CNGB1 expression in tissue samples, particularly in studies involving retinal tissue and cancer research .

The applications of CNGB1 antibodies include:

When designing experiments, researchers should consider that optimal antibody dilutions may vary based on the specific experimental conditions, sample types, and detection systems employed. It is recommended to validate each antibody in your specific experimental system before proceeding with larger-scale analyses.

What species reactivity do commercial CNGB1 antibodies typically show?

Commercial CNGB1 antibodies display reactivity with various species, with human and mouse samples being the most commonly validated targets. According to the search results, specific products like the 30557-1-AP antibody from Proteintech demonstrate confirmed reactivity with human and mouse samples . Similarly, the PACO06363 antibody from Assay Genie shows reactivity with human, mouse, and rat samples .

For experimental design, it's crucial to verify species cross-reactivity when working with non-human models. The conservation of CNGB1 epitopes across species may vary, potentially affecting antibody recognition. If working with species not listed as validated, preliminary testing is strongly recommended.

How should I optimize Western Blot protocols for CNGB1 detection?

Optimizing Western blot protocols for CNGB1 detection requires careful consideration of several parameters due to the protein's high molecular weight and potential for post-translational modifications. Based on the search results, the following approach is recommended:

• Sample preparation: For retinal tissue samples, use appropriate extraction buffers with protease inhibitors to prevent degradation . Cell line samples (e.g., NIH-3T3, J82, 253JB-V) have been successfully used for CNGB1 detection .

• Antibody dilution: Start with the manufacturer's recommended range (typically 1:500-1:1000 for primary antibodies like 30557-1-AP) . Optimization may be necessary depending on your specific samples and detection system.

• Molecular weight considerations: Be aware that the observed molecular weight of CNGB1 (approximately 240 kDa) differs significantly from the calculated molecular weight (140 kDa) . This discrepancy is likely due to post-translational modifications and should be considered when interpreting results.

• Detection system: Use high-sensitivity chemiluminescence or fluorescence-based detection systems, as appropriate for your experiment.

• Controls: Include positive controls such as mouse retina tissue, which has been validated for CNGB1 expression , and appropriate negative controls.

Following manufacturer-specific protocols is recommended for initial experiments, with subsequent optimization based on your specific research conditions.

What are the recommended storage conditions for CNGB1 antibodies?

Proper storage of CNGB1 antibodies is crucial for maintaining their stability and binding activity over time. According to the search results, the following storage conditions are typically recommended:

• Storage temperature: Store at -20°C . This temperature is commonly recommended for antibody preservation.

• Buffer composition: Antibodies are typically provided in PBS with 0.02% sodium azide and 50% glycerol (pH 7.3) , or similar buffers that promote stability.

• Stability period: When stored properly, antibodies are generally stable for one year after shipment .

• Aliquoting considerations: For the 30557-1-AP antibody, aliquoting is noted as unnecessary for -20°C storage , but this may vary for other products. Generally, repeated freeze-thaw cycles should be avoided.

• Small volume considerations: Some preparations (20 μL sizes) may contain 0.1% BSA as a stabilizer .

Always refer to the specific storage instructions provided by the manufacturer of your particular antibody to ensure optimal performance in your experiments.

Why is there a discrepancy between calculated and observed molecular weights for CNGB1?

The discrepancy between the calculated molecular weight (140 kDa) and observed molecular weight (240 kDa) of CNGB1 is a significant consideration for researchers . This phenomenon is attributed to several factors:

• Post-translational modifications: CNGB1 undergoes extensive post-translational modifications, particularly glycosylation, which can substantially increase its apparent molecular weight in gel electrophoresis.

• Protein structure: The elongated structure of CNGB1, with its six transmembrane domains and large cytoplasmic regions, contributes to anomalous migration during SDS-PAGE.

• Isoform variation: CNGB1 exists in multiple splice variants, potentially affecting the observed molecular weight depending on the variant expressed in your experimental system.

This discrepancy underscores the importance of using positive controls when first implementing CNGB1 Western blots. Researchers should anticipate detecting bands at approximately 240 kDa rather than at the calculated 140 kDa position. When reporting results, it is advisable to acknowledge this established discrepancy and cite previous literature documenting this observation.

What role does CNGB1 play in response to chemotherapy treatments?

Recent research has identified CNGB1 as a potential predictor of response to neoadjuvant chemotherapy (NAC), particularly in muscle-invasive bladder cancer (MIBC) . The search results reveal several important findings:

• Predictive biomarker potential: CNGB1 expression levels correlate with response to chemotherapy treatments. Patients with low CNGB1 expression ("CNGB1lo") showed better response to treatment compared to those with high expression ("CNGB1hi") .

• Survival correlation: Kaplan-Meier analysis demonstrated that CNGB1 expression correlates with cancer-specific survival (p < 0.001), suggesting prognostic value beyond treatment response prediction .

• Functional validation: Experimental knockdown of CNGB1 in bladder cancer cell lines (J82 and 253JB-V) enhanced sensitivity to cisplatin treatment, providing mechanistic support for the clinical observations .

These findings suggest that CNGB1 may be involved in cellular mechanisms of chemoresistance. The data indicates:

For researchers investigating cancer therapeutics, these findings highlight CNGB1 as a potential target for combination therapy approaches or as a biomarker for patient stratification in clinical trials.

How can I validate CNGB1 antibody specificity for my specific research application?

Validating antibody specificity is critical for ensuring reliable and reproducible results. For CNGB1 antibodies, consider implementing the following validation approaches:

• Positive and negative controls: Use tissues or cell lines with known CNGB1 expression levels. Mouse retina tissue has been validated as a positive control for CNGB1 detection , while appropriate negative controls might include tissues where CNGB1 is not expressed or CNGB1 knockout models.

• siRNA knockdown validation: As demonstrated in the bladder cancer studies, CNGB1 knockdown using siRNA provides an excellent specificity control . Western blotting after knockdown should show reduced band intensity at the expected 240 kDa position.

• Immunogen competition: Pre-incubating the antibody with the immunogenic peptide (if available) should block specific binding. The 30557-1-AP antibody, for example, was generated against a CNGB1 fusion protein (Ag22914) .

• Multiple antibody validation: Use different antibodies targeting distinct epitopes of CNGB1 to confirm specificity.

• Orthogonal methods: Correlate protein detection with mRNA expression using methods like RT-qPCR.

For tissue microarray analysis, a scoring system has been established, where 'high' expression is defined as any single score ≥ 2.5 or an average score of ≥1.5, and 'low' expression as any score ≤ 1 . This standardized approach aids in reducing subjective interpretation of results.

What are the best practices for quantifying CNGB1 expression in tissue samples?

Quantifying CNGB1 expression in tissue samples requires careful methodology to ensure reproducible and meaningful results. Based on the search results, researchers have successfully employed the following approaches:

• Immunohistochemistry scoring systems: For tissue microarrays, a defined scoring system has been implemented, where scores ≥ 2.5 (or average scores ≥ 1.5) indicate high expression, while scores ≤ 1 indicate low expression . This allows for semi-quantitative assessment of protein levels.

• Western blot quantification: When using Western blot analysis:

  • Include loading controls (e.g., α-tubulin has been used successfully)

  • Use appropriate software for densitometric analysis

  • Express results as relative values compared to controls

  • Perform biological replicates (n ≥ 3) for statistical validity

• Gene expression profiling: For mRNA-level quantification, techniques such as microarray analysis or qRT-PCR can complement protein-level measurements.

How can CNGB1 expression be effectively knocked down in experimental models?

Based on the search results, siRNA-mediated knockdown has been successfully employed to reduce CNGB1 expression in experimental models . The following methodology has proven effective:

• Transfection approach: Reverse transfection using RNAiMax (Invitrogen) according to the manufacturer's protocol has been used successfully .

• siRNA concentration: A concentration of 25 nM siRNA has been effective for CNGB1 knockdown .

• Experimental timeline: A 48-hour knockdown period before subsequent treatments (e.g., cisplatin) has provided sufficient reduction in CNGB1 expression .

• Validation: Western blot analysis using CNGB1-specific antibodies can confirm successful knockdown. α-tubulin is recommended as a loading control .

• Functional assessment: Following knockdown, functional assays such as cell viability tests (e.g., Sulforhodamine B assay) can be performed to assess the impact of CNGB1 reduction .

The detailed protocol described in the search results includes:

• Seeding cells at specific densities (e.g., 2.5-3 × 10³ cells/well) in 100 μL tissue culture medium

• Using six wells per experimental arm for statistical robustness

• Treating cells with appropriate drug concentrations (e.g., cisplatin at GI50 concentrations) following the knockdown period

• Quantifying results using colorimetric assays with absorbance measurement at 570 nm

This approach has successfully demonstrated that CNGB1 knockdown enhances cisplatin sensitivity in bladder cancer cell lines, providing valuable insights into CNGB1's functional role.

What emerging roles of CNGB1 are being investigated beyond sensory transduction?

While CNGB1 is traditionally associated with sensory transduction in the retina and olfactory epithelium , recent research has uncovered potential roles in other biological processes. The search results highlight several emerging areas of investigation:

• Cancer biology: CNGB1 has been identified as a potential predictor of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer, suggesting a role in treatment resistance mechanisms . This opens avenues for investigating CNGB1's function in cellular survival pathways and DNA damage responses.

• Signal transduction beyond sensory systems: The presence of CNGB1 in various non-neuronal cells suggests broader roles in cellular signaling beyond classic sensory transduction .

• Therapeutic targeting: The finding that CNGB1 knockdown enhances cisplatin sensitivity suggests potential for therapeutic interventions targeting this protein or its associated pathways .

• Biomarker development: The correlation between CNGB1 expression and cancer-specific survival indicates potential applications in prognostic biomarker development .

These emerging roles suggest that CNGB1 functions extend beyond its canonical ion channel modulatory activity. Future research directions might include mechanistic studies of how CNGB1 contributes to chemoresistance, investigation of CNGB1 interaction partners in different cellular contexts, and exploration of CNGB1 as a therapeutic target in various disease states.

How do different CNGB1 isoforms affect antibody selection and experimental design?

CNGB1 exists in multiple isoforms, which has important implications for antibody selection and experimental design. While the search results do not explicitly detail all isoforms, they provide insights into considerations for researchers:

• Antibody epitope location: The immunogen used for 30557-1-AP is described as "CNGB1 fusion protein Ag22914" , while the PACO06363 antibody was raised against a "synthesized peptide derived from the Internal region of human CNG-1 β" . The specific epitope location determines which isoforms will be recognized.

• Molecular weight considerations: The observed molecular weight of 240 kDa likely represents the full-length CNGB1 isoform. Researchers should be aware that shorter isoforms may appear at different molecular weights in Western blots.

• Tissue-specific expression: Different tissues may express specific CNGB1 isoforms preferentially. The retina, for example, has been validated for CNGB1 detection , but researchers working with other tissues should validate the presence of their isoform of interest.

• Experimental design implications: When designing knockdown experiments or expression studies, consider:

  • Target regions common to all isoforms of interest

  • Verify which isoforms are expressed in your experimental system

  • Select antibodies that recognize epitopes present in your isoforms of interest

For comprehensive studies, researchers might consider using multiple antibodies targeting different regions of the protein to distinguish between isoforms and ensure complete coverage of all CNGB1 variants relevant to their research question.